Neomics Pharmaceuticals

Neomics Pharmaceuticals, founded in 2017 and based in Paris, is a preclinical biotech innovator in the cell and gene therapy space. The company's core technology is a proprietary third-generation CAR platform designed to overcome historical expression challenges, aiming to produce T cell therapies with superior expansion, persistence, and clinical efficacy. While still in early development, Neomics is building a pipeline of TCR-T and CAR-T candidates targeting a broad range of cancers, positioning itself in the competitive but high-potential field of next-generation immuno-oncology.

Proprietary third-generation CAR platform combining CD28 and 41BB co-stimulatory domains with solved protein expression challenges, coupled with immunogenomics for TCR discovery.

Neomics operates in the highly competitive cell therapy arena, competing with large pharma (e.g., Novartis, Gilead, Bristol Myers Squibb) and numerous biotechs developing next-gen CAR constructs (e.g., with logic-gated or armoring technologies) and novel TCR therapies. Differentiation hinges on proving superior efficacy from its specific dual-signaling architecture.